MicroRNA-based therapeutics in cardiovascular disease: screening and delivery to the target

Biochemical Society Transactions

Volumn 46, Issue 1, 2018, Pages 11-21

  Mellis, David ^a   Caporali, Andrea ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; COBOMARSEN; MICRORNA; MICRORNA 29; MIRAVIRSEN; OLIGONUCLEOTIDE; SMALL INTERFERING RNA; TEMAVIRSEN; VIRUS VECTOR; MESSENGER RNA;

CARDIAC MUSCLE CELL; CARDIOVASCULAR DISEASE; CELL FUNCTION; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENDOSOME; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE FUNCTION; GENE THERAPY; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYSOSOME; MOLECULAR BIOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; VIRAL GENE DELIVERY SYSTEM; 3' UNTRANSLATED REGION; CARDIAC MUSCLE; DRUG DELIVERY SYSTEM; GENETICS; METABOLISM;

3' UNTRANSLATED REGIONS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; MICRORNAS; MYOCARDIUM; RNA, MESSENGER;

EID: 85046845971     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20170037     Document Type: Review

References (82)

1. Esteller, M. (2011) Non-coding RNAs in human disease. Nat. Rev. Genet. 12, 861–874 https://doi.org/10.1038/nrg3074
2. Alexander, R.P., Fang, G., Rozowsky, J., Snyder, M. and Gerstein, M.B. (2010) Annotating non-coding regions of the genome. Nat. Rev. Genet. 11, 559–571 https://doi.org/10.1038/nrg2814
3. Sonenberg, N. and Hinnebusch, A.G. (2009) Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136, 731–745 https://doi.org/10.1016/j.cell.2009.01.042
4. Cech, T.R. and Steitz, J.A. (2014) The noncoding RNA revolution—trashing old rules to forge new ones. Cell 157, 77–94 https://doi.org/10.1016/j.cell.2014.03.008
5. Ulitsky, I. and Bartel, D.P. (2013) lincRNAs: genomics, evolution, and mechanisms. Cell 154, 26–46 https://doi.org/10.1016/j.cell.2013.06.020
6. Quinn, J.J. and Chang, H.Y. (2016) Unique features of long non-coding RNA biogenesis and function. Nat. Rev. Genet. 17, 47–62 https://doi.org/10.1038/nrg.2015.10
7. Lee, R.C., Feinbaum, R.L. and Ambros, V. (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843–854 https://doi.org/10.1016/0092-8674(93)90529-Y
8. Bartel, D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297 https://doi.org/10.1016/S0092-8674(04)00045-5
9. Ghildiyal, M. and Zamore, P.D. (2009) Small silencing RNAs: an expanding universe. Nat. Rev. Genet. 10, 94–108 https://doi.org/10.1038/nrg2504
10. Jonas, S. and Izaurralde, E. (2015) Towards a molecular understanding of microRNA-mediated gene silencing. Nat. Rev. Genet. 16, 421–433 https://doi.org/10.1038/nrg3965
11. Agarwal, V., Bell, G.W., Nam, J.-W. and Bartel, D.P. (2015) Predicting effective microRNA target sites in mammalian mRNAs. eLife 4, e05005 https://doi.org/10.7554/eLife.05005
12. Huntzinger, E. and Izaurralde, E. (2011) Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat. Rev. Genet. 12, 99–110 https://doi.org/10.1038/nrg2936
13. Hausser, J., Syed, A.P., Bilen, B. and Zavolan, M. (2013) Analysis of CDS-located miRNA target sites suggests that they can effectively inhibit translation. Genome Res. 23, 604–615 https://doi.org/10.1101/gr.139758.112
14. Hausser, J. and Zavolan, M. (2014) Identification and consequences of miRNA–target interactions—beyond repression of gene expression. Nat. Rev. Genet. 15, 599–612 https://doi.org/10.1038/nrg3765
15. 0-UTR interaction sites. Genome Res. 19, 1175–1183 https://doi.org/10.1101/gr.089367.108
16. Iorio, M.V. and Croce, C.M. (2012) MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol. Med. 4, 143–159 https://doi.org/10.1002/emmm.201100209
17. Barwari, T., Joshi, A. and Mayr, M. (2016) MicroRNAs in cardiovascular disease. J. Am. Coll. Cardiol. 68, 2577–2584 https://doi.org/10.1016/j.jacc.2016.09.945
18. Hebert, S.S. and De Strooper, B. (2007) Molecular biology: miRNAs in neurodegeneration. Science 317, 1179–1180 https://doi.org/10.1126/science. 1148530
19. Li, Z. and Rana, T.M. (2014) Therapeutic targeting of microRNAs: current status and future challenges. Nat. Rev. Drug Discov. 13, 622–638 https://doi.org/10.1038/nrd4359
20. Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, O. et al. (2008) LNA-mediated microRNA silencing in non-human primates. Nature 452, 896–899 https://doi.org/10.1038/nature06783
21. Cappola, T.P. and Margulies, K.B. (2011) Functional genomics applied to cardiovascular medicine. Circulation 124, 87–94 https://doi.org/10.1161/CIRCULATIONAHA.111.027300
22. Boutros, M., Heigwer, F. and Laufer, C. (2015) Microscopy-based high-content screening. Cell 163, 1314–1325 https://doi.org/10.1016/j.cell.2015.11. 007
23. Simpson, K.J. and Smith, J.A. (2017) Knocking down the obstacles to functional genomics data sharing. Sci. Data 4, 170019 https://doi.org/10.1038/sdata.2017.19
24. Pegoraro, G. and Misteli, T. (2017) High-throughput imaging for the discovery of cellular mechanisms of disease. Trends Genet. 33, 604–615 https://doi.org/10.1016/j.tig.2017.06.005
25. Lemons, D., Maurya, M.R., Subramaniam, S. and Mercola, M. (2013) Developing microRNA screening as a functional genomics tool for disease research. Front. Physiol. 4, 223 https://doi.org/10.3389/fphys.2013.00223
26. Steinkraus, B.R., Toegel, M. and Fulga, T.A. (2016) Tiny giants of gene regulation: experimental strategies for microRNA functional studies. Wiley Interdiscip. Rev. Dev. Biol. 5, 311–362 https://doi.org/10.1002/wdev.223
27. Keklikoglou, I., Koerner, C., Schmidt, C., Zhang, J.D., Heckmann, D., Shavinskaya, A. et al. (2012) MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways. Oncogene 31, 4150–4163 https://doi.org/10.1038/onc.2011.571
28. Judson, R.L., Greve, T.S., Parchem, R.J. and Blelloch, R. (2013) MicroRNA-based discovery of barriers to dedifferentiation of fibroblasts to pluripotent stem cells. Nat. Struct. Mol. Biol. 20, 1227–1235 https://doi.org/10.1038/nsmb.2665
29. Maudet, C., Mano, M., Sunkavalli, U., Sharan, M., Giacca, M., Förstner, K.U. et al. (2014) Functional high-throughput screening identifies the miR-15 microRNA family as cellular restriction factors for Salmonella infection. Nat. Commun. 5, 4718 https://doi.org/10.1038/ncomms5718
30. Zhang, H., Hao, Y., Yang, J., Zhou, Y., Li, J., Yin, S. et al. (2011) Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis. Nat. Commun. 2, 554 https://doi.org/10.1038/ncomms1555
31. Huang, Q., Gumireddy, K., Schrier, M., le Sage, C., Nagel, R., Nair, S. et al. (2008) The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat. Cell Biol. 10, 202–210 https://doi.org/10.1038/ncb1681
32. Jentzsch, C., Leierseder, S., Loyer, X., Flohrschütz, I., Sassi, Y., Hartmann, D. et al. (2012) A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. J. Mol. Cell. Cardiol. 52, 13–20 https://doi.org/10.1016/j.yjmcc.2011.07.010
33. Eulalio, A., Mano, M., Ferro, M.D., Zentilin, L., Sinagra, G., Zacchigna, S. et al. (2012) Functional screening identifies miRNAs inducing cardiac regeneration. Nature 492, 376–381 https://doi.org/10.1038/nature11739
34. Wahlquist, C., Jeong, D., Rojas-Muñoz, A., Kho, C., Lee, A., Mitsuyama, S. et al. (2014) Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 508, 531–535 https://doi.org/10.1038/nature13073
35. Elmén, J., Lindow, M., Silahtaroglu, A., Bak, M., Christensen, M., Lind-Thomsen, A. et al. (2008) Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 36, 1153–1162 https://doi.org/10.1093/nar/gkm1113
36. Fiedler, J., Stöhr, A., Gupta, S.K., Hartmann, D., Holzmann, A., Just, A. et al. (2014) Functional microRNA library screening identifies the hypoxamir miR-24 as a potent regulator of smooth muscle cell proliferation and vascularization. Antioxid. Redox Signal. 21, 1167–1176 https://doi.org/10.1089/ars.2013.5418
37. Rupaimoole, R. and Slack, F.J. (2017) MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov. 16, 203–222 https://doi.org/10.1038/nrd.2016.246
38. Matsui, M. and Corey, D.R. (2017) Non-coding RNAs as drug targets. Nat. Rev. Drug Discov. 16, 167–179 https://doi.org/10.1038/nrd.2016.117
39. Adams, B.D., Parsons, C., Walker, L., Zhang, W.C. and Slack, F.J. (2017) Targeting noncoding RNAs in disease. J. Clin. Invest. 127, 761–771 https://doi.org/10.1172/JCI84424
40. Trajkovski, M., Hausser, J., Soutschek, J., Bhat, B., Akin, A., Zavolan, M. et al. (2011) MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474, 649–653 https://doi.org/10.1038/nature10112
41. van Zandwijk, N., Pavlakis, N., Kao, S.C., Linton, A., Boyer, M.J., Clarke, S. et al. (2017) Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 18, 1386–1396 https://doi.org/10.1016/S1470-2045(17)30621-6
42. Maurer, B., Stanczyk, J., Jüngel, A., Akhmetshina, A., Trenkmann, M., Brock, M. et al. (2010) MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 62, 1733–1743 https://doi.org/10.1002/art.27443
43. Bader, A.G. (2012) miR-34 — a microRNA replacement therapy is headed to the clinic. Front. Genet. 3, 120 https://doi.org/10.3389/fgene.2012. 00120
44. Babar, I.A., Cheng, C.J., Booth, C.J., Liang, X., Weidhaas, J.B., Saltzman, W.M. et al. (2012) Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc. Natl Acad. Sci. U.S.A. 109, E1695–E1704 https://doi.org/10.1073/pnas.1201516109
45. Gomez, I.G., MacKenna, D.A., Johnson, B.G., Kaimal, V., Roach, A.M., Ren, S. et al. (2015) Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J. Clin. Invest. 125, 141–156 https://doi.org/10.1172/JCI75852
46. Samanta, S., Balasubramanian, S., Rajasingh, S., Patel, U., Dhanasekaran, A., Dawn, B. et al. (2016) MicroRNA: a new therapeutic strategy for cardiovascular diseases. Trends Cardiovasc. Med. 26, 407–419 https://doi.org/10.1016/j.tcm.2016.02.004
47. Kwekkeboom, R.F.J., Lei, Z., Doevendans, P.A., Musters, R.J.P. and Sluijter, J.P.G. (2014) Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges. Clin. Sci. 127, 351–365 https://doi.org/10.1042/CS20140005
48. Boon, R.A. and Dimmeler, S. (2015) MicroRNAs in myocardial infarction. Nat. Rev. Cardiol. 12, 135–142 https://doi.org/10.1038/nrcardio.2014.207
49. Hullinger, T.G., Montgomery, R.L., Seto, A.G., Dickinson, B.A., Semus, H.M., Lynch, J.M. et al. (2012) Inhibition of miR-15 protects against cardiac ischemic injury. Circ. Res. 110, 71–81 https://doi.org/10.1161/CIRCRESAHA.111.244442
50. Porrello, E.R., Mahmoud, A.I., Simpson, E., Johnson, B.A., Grinsfelder, D., Canseco, D. et al. (2013) Regulation of neonatal and adult mammalian heart regeneration by the miR-15 family. Proc. Natl Acad. Sci. U.S.A. 110, 187–192 https://doi.org/10.1073/pnas.1208863110
51. Meloni, M., Marchetti, M., Garner, K., Littlejohns, B., Sala-Newby, G., Xenophontos, N. et al. (2013) Local inhibition of microRNA-24 improves reparative angiogenesis and left ventricle remodeling and function in mice with myocardial infarction. Mol. Ther. 21, 1390–1402 https://doi.org/10.1038/mt.2013. 89
52. Fiedler, J., Jazbutyte, V., Kirchmaier, B.C., Gupta, S.K., Lorenzen, J., Hartmann, D. et al. (2011) MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 124, 720–730 https://doi.org/10.1161/CIRCULATIONAHA.111.039008
53. Qian, L., Van Laake, L.W., Huang, Y., Liu, S., Wendland, M.F. and Srivastava, D. (2011) miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. J. Exp. Med. 208, 549–560 https://doi.org/10.1084/jem.20101547
54. Caporali, A. and Emanueli, C. (2011) MicroRNA regulation in angiogenesis. Vascul. Pharmacol. 55, 79–86 https://doi.org/10.1016/j.vph.2011.06.006
55. Caporali, A. and Emanueli, C. (2012) MicroRNAs in postischemic vascular repair. Cardiol. Res. Pract. 2012, 1–7 https://doi.org/10.1155/2012/486702
56. Welten, S.M.J., Bastiaansen, A.J.N.M., de Jong, R.C.M., de Vries, M.R., Peters, E.A.B., Boonstra, M.C. et al. (2014) Inhibition of 14q32 MicroRNAs miR-329, miR-487b, miR-494, and miR-495 increases neovascularization and blood flow recovery after ischemia. Circ. Res. 115, 696–708 https://doi.org/10.1161/CIRCRESAHA.114.304747
57. Dowdy, S.F. (2017) Overcoming cellular barriers for RNA therapeutics. Nat. Biotechnol. 35, 222–229 https://doi.org/10.1038/nbt.3802
58. Gurda, B.L., De Guilhem De Lataillade, A., Bell, P., Zhu, Y., Yu, H., Wang, P. et al. (2016) Evaluation of AAV-mediated gene therapy for central nervous system disease in canine mucopolysaccharidosis VII. Mol. Ther. 24, 206–216 https://doi.org/10.1038/mt.2015.189
59. Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M.F. et al. (2010) Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21, 704–712 https://doi.org/10.1089/hum.2009.182
60. Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J. et al. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342–347 https://doi.org/10.1038/nm1358
61. Zincarelli, C., Soltys, S., Rengo, G. and Rabinowitz, J.E. (2008) Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073–1080 https://doi.org/10.1038/mt.2008.76
62. Müller, O.J., Leuchs, B., Pleger, S.T., Grimm, D., Franz, W.-M., Katus, H.A. et al. (2006) Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc. Res. 70, 70–78 https://doi.org/10.1016/j.cardiores.2005.12.017
63. Yin, H., Kanasty, R.L., Eltoukhy, A.A., Vegas, A.J., Dorkin, J.R. and Anderson, D.G. (2014) Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15, 541–555 https://doi.org/10.1038/nrg3763
64. Kauffman, K.J., Webber, M.J. and Anderson, D.G. (2016) Materials for non-viral intracellular delivery of messenger RNA therapeutics. J. Control. Release 240, 227–234 https://doi.org/10.1016/j.jconrel.2015.12.032
65. Lesizza, P., Prosdocimo, G., Martinelli, V., Sinagra, G., Zacchigna, S. and Giacca, M. (2017) Single-dose intracardiac injection of pro-regenerative microRNAs improves cardiac function after myocardial infarction. Circ. Res. 120, 1298–1304 https://doi.org/10.1161/CIRCRESAHA.116.309589
66. Simón-Yarza, T., Formiga, F.R., Tamayo, E., Pelacho, B., Prosper, F. and Blanco-Prieto, M.J. (2012) Vascular endothelial growth factor-delivery systems for cardiac repair: an overview. Theranostics 2, 541–552 https://doi.org/10.7150/thno.3682
67. Masotti, A., Miller, M.R., Celluzzi, A., Rose, L., Micciulla, F., Hadoke, P.W.F. et al. (2016) Regulation of angiogenesis through the efficient delivery of microRNAs into endothelial cells using polyamine-coated carbon nanotubes. Nanomedicine 12, 1511–1522 https://doi.org/10.1016/j.nano.2016.02.017
68. Dahlman, J.E., Barnes, C., Khan, O., Thiriot, A., Jhunjunwala, S., Shaw, T.E. et al. (2014) In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat. Nanotechnol. 9, 648–655 https://doi.org/10.1038/nnano.2014.84
69. Papangeli, I., Kim, J., Maier, I., Park, S., Lee, A., Kang, Y. et al. (2016) MicroRNA 139-5p coordinates APLNR-CXCR4 crosstalk during vascular maturation. Nat. Commun. 7, 11268 https://doi.org/10.1038/ncomms11268
70. Kwekkeboom, R.F.J., Sluijter, J.P.G., van Middelaar, B.J., Metz, C.H., Brans, M.A. Kamp, O. et al. (2016) Increased local delivery of antagomir therapeutics to the rodent myocardium using ultrasound and microbubbles. J. Control. Release 222, 18–31 https://doi.org/10.1016/j.jconrel.2015.11. 020
71. De Cock, I., Zagato, E., Braeckmans, K., Luan, Y., de Jong, N., De Smedt, S.C. et al. (2015) Ultrasound and microbubble mediated drug delivery: acoustic pressure as determinant for uptake via membrane pores or endocytosis. J. Control. Release 197, 20–28 https://doi.org/10.1016/j.jconrel.2014.10.031
72. Su, Q., Li, L., Liu, Y., Zhou, Y., Wang, J. and Wen, W. (2015) Ultrasound-targeted microbubble destruction-mediated microRNA-21 transfection regulated PDCD4/NF-κB/TNF-α pathway to prevent coronary microembolization-induced cardiac dysfunction. Gene Ther. 22, 1000–1006 https://doi.org/10.1038/gt.2015.59
73. Ylä-Herttuala, S., Bridges, C., Katz, M.G. and Korpisalo, P. (2017) Angiogenic gene therapy in cardiovascular diseases: dream or vision? Eur. Heart J. 38, 1365–1371 https://doi.org/10.1093/eurheartj/ehw547
74. Hulot, J.-S., Ishikawa, K. and Hajjar, R.J. (2016) Gene therapy for the treatment of heart failure: promise postponed. Eur. Heart J. 37, 1651–1658 https://doi.org/10.1093/eurheartj/ehw019
75. Katz, M.G., Fargnoli, A.S., Pritchette, L.A. and Bridges, C.R. (2012) Gene delivery technologies for cardiac applications. Gene Ther. 19, 659–669 https://doi.org/10.1038/gt.2012.11
76. Poggioli, T., Sarathchandra, P., Rosenthal, N. and Santini, M.P. (2014) Intramyocardial cell delivery: observations in murine hearts. J. Vis. Exp. 83, e51064 https://doi.org/10.3791/51064
77. Kajander, S., Joutsiniemi, E., Saraste, M., Pietila, M., Ukkonen, H., Saraste, A. et al. (2010) Cardiac positron emission tomography/computed tomography imaging accurately detects anatomically and functionally significant coronary artery disease. Circulation 122, 603–613 https://doi.org/10.1161/CIRCULATIONAHA.109.915009
78. Hassinen, I., Kivelä, A., Hedman, A., Saraste, A., Knuuti, J., Hartikainen, J.E. et al. (2016) Intramyocardial gene therapy directed to hibernating heart muscle using a combination of electromechanical mapping and positron emission tomography. Hum. Gene Ther. 27, 830–834 https://doi.org/10.1089/hum.2016.131
79. Small, E.M. and Olson, E.N. (2011) Pervasive roles of microRNAs in cardiovascular biology. Nature 469, 336–342 https://doi.org/10.1038/nature09783
80. Bhattarai, S.R., Muthuswamy, E., Wani, A., Brichacek, M., Castañeda, A.L., Brock, S.L. et al. (2010) Enhanced gene and siRNA delivery by polycation-modified mesoporous silica nanoparticles loaded with chloroquine. Pharm. Res. 27, 2556–2568 https://doi.org/10.1007/ s11095-010-0245-0
81. Sanjana, N.E., Shalem, O. and Zhang, F. (2014) Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783–784 https://doi.org/10.1038/nmeth.3047
82. Liu, S.J., Horlbeck, M.A., Cho, S.W., Birk, H.S., Malatesta, M., He, D. et al. (2017) CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells. Science 355, eaah7111 https://doi.org/10.1126/science.aah7111